Literature DB >> 15231507

How the type of risk reduction influences required sample sizes in randomised clinical trials.

K Bruynesteyn1, A Wanders, R Landewé, D van der Heijde.   

Abstract

To increase change between groups, randomised clinical trials (RCT) often include patients with high risk for a particular outcome, by inclusion criteria that select predictors for that outcome. This increases the statistical power, and fewer patients are required for that RCT. The way in which patient selection influences the power, and thus sample size required, depends on how an intervention reduces the individual risk: by an absolute or relative risk reduction model.

Entities:  

Mesh:

Year:  2004        PMID: 15231507      PMCID: PMC1754827          DOI: 10.1136/ard.2003.014035

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Commentary: relative treatment effects are consistent across the spectrum of underlying risks...usually.

Authors:  Finlay A McAlister
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

Review 2.  Interaction revisited: the difference between two estimates.

Authors:  Douglas G Altman; J Martin Bland
Journal:  BMJ       Date:  2003-01-25

3.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

4.  Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.

Authors:  M Boers; P J Kostense; A C Verhoeven; S van der Linden
Journal:  Arthritis Rheum       Date:  2001-10

5.  The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up.

Authors:  T Uhlig; L M Smedstad; P Vaglum; T Moum; N Gérard; T K Kvien
Journal:  Rheumatology (Oxford)       Date:  2000-07       Impact factor: 7.580

6.  Can overall results of clinical trials be applied to all patients?

Authors:  P M Rothwell
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

7.  Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  B Combe; M Dougados; P Goupille; A Cantagrel; J F Eliaou; J Sibilia; O Meyer; J Sany; J P Daurès; A Dubois
Journal:  Arthritis Rheum       Date:  2001-08

8.  Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup.

Authors:  K W Drossaers-Bakker; A H Zwinderman; T P M Vliet Vlieland; D Van Zeben; K Vos; F C Breedveld; J M W Hazes
Journal:  Arthritis Rheum       Date:  2002-08

9.  Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial.

Authors:  A H Gerards; R B M Landewé; A P A Prins; G A W Bruyn; H S Goei Thé; R F J M Laan; B A C Dijkmans; G A W Bruijn
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

10.  Number needed to treat (NNT): implication in rheumatology clinical practice.

Authors:  M Osiri; M E Suarez-Almazor; G A Wells; V Robinson; P Tugwell
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

View more
  1 in total

1.  Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up.

Authors:  K Bruynesteyn; R Landewé; Sj van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.